Roles of phosphatidylinositol-3-kinases signaling pathway in inflammation-related cancer: Impact of rs10889677 variant and buparlisib in colitis-associated cancer

Figure 8 The relative gene expression for Pdk1 and Sgk2. A: The relative gene expression of Pdk1 in colitis-associated cancer (CAC)-induced mice showed no significant difference between buparlisib treated and untreated group; B: In CAC-induced mice, buparlisib treatment demonstrated a significantly reduced expression of Sgk2.^aP < 0.05 (compared to the control group); ^cP < 0.05 (compared to the CAC untreated group); data are presented as mean ± SEM; one-way ANOVA was employed; n = 4-8. CAC: Colitis-associated cancer; DDCT: Delta-delta CT; Pdk1: Phosphoinositide-dependent kinase 1; Sgk2: Serum/glucocorticoid regulated kinase 2.